JLE

European Journal of Dermatology

MENU

Considerations on SARS-Cov-2 vaccines in patients with autoimmune blistering diseases Volume 31, numéro 3, May-June 2021

Auteurs
1 Section of Dermatology, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
2 Dermatology Unit, San Martino Policlinic Hospital IRCCS, Genoa, Italy
3 Department of Experimental Medicine (DIMES), University of Genoa, Genoa, Italy
4 Section of Public Health, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
5 Hygiene Unit, San Martino Policlinic Hospital IRCCS, Genoa, Italy

Patients affected by autoimmune bullous diseases (AIBDs) are fragile due to immunosuppressive treatment. Infections, favoured by immunosuppression, represent an important cause of death in AIBD patients [1]. No specific dermatological guidelines address the SARS-CoV-2 vaccination issue in AIBD patients [1]. According to general guidelines for AIBD management, patients receiving immunosuppressive therapy should receive non-live vaccinations (e.g. against seasonal influenza, pneumococcal infection), [...]